Format

Send to

Choose Destination
J Neurosurg. 2018 Dec 21:1-10. doi: 10.3171/2018.7.JNS18656. [Epub ahead of print]

Resection and permanent intracranial brachytherapy using modular, biocompatible cesium-131 implants: results in 20 recurrent, previously irradiated meningiomas.

Author information

1
Departments of1Radiation Oncology.
2
3Neurology, Barrow Neurological Institute, and.
3
2Neurosurgery, and.
4
4St. Joseph's Hospital and Medical Center, Phoenix, Arizona; and.
5
5Lovelace Medical Center, Albuquerque, New Mexico.

Abstract

OBJECTIVEEffective treatments for recurrent, previously irradiated intracranial meningiomas are limited, and resection alone is not usually curative. Thus, the authors studied the combination of maximum safe resection and adjuvant radiation using permanent intracranial brachytherapy (R+BT) in patients with recurrent, previously irradiated aggressive meningiomas.METHODSPatients with recurrent, previously irradiated meningiomas were treated between June 2013 and October 2016 in a prospective single-arm trial of R+BT. Cesium-131 (Cs-131) radiation sources were embedded in modular collagen carriers positioned in the operative bed on completion of resection. The Cox proportional hazards model with this treatment as a predictive term was used to model its effect on time to local tumor progression.RESULTSNineteen patients (median age 64.5 years, range 50-78 years) with 20 recurrent, previously irradiated tumors were treated. The WHO grade at R+BT was I in 4 (20%), II in 14 (70%), and III in 2 (10%) cases. The median number of prior same-site radiation courses and same-site surgeries were 1 (range 1-3) and 2 (range 1-4), respectively; the median preoperative tumor volume was 11.3 cm3 (range 0.9-92.0 cm3). The median radiation dose from BT was 63 Gy (range 54-80 Gy). At a median radiographic follow-up of 15.4 months (range 0.03-47.5 months), local failure (within 1.5 cm of the implant bed) occurred in 2 cases (10%). The median treatment-site time to progression after R+BT has not been reached; that after the most recent prior therapy was 18.3 months (range 3.9-321.9 months; HR 0.17, p = 0.02, log-rank test). The median overall survival after R+BT was 26 months, with 9 patient deaths (47% of patients). Treatment was well tolerated; 2 patients required surgery for complications, and 2 experienced radiation necrosis, which was managed medically.CONCLUSIONSR+BT utilizing Cs-131 sources in modular carriers represents a potentially safe and effective treatment option for recurrent, previously irradiated aggressive meningiomas.

KEYWORDS:

BT = brachytherapy; CTCAE = Common Terminology Criteria for Adverse Events; Cs = cesium; EBRT = external-beam radiation therapy; GTR = gross-total resection; HR = hazard ratio; NGTR = near gross-total resection (≥ 90%); PFS = progression-free survival; R+BT = resection and BT; STR = subtotal resection; TTP = time to progression; brachytherapy; cesium-131; implants; intraoperative; meningiomas; oncology; recurrent

PMID:
30579269
DOI:
10.3171/2018.7.JNS18656

Supplemental Content

Full text links

Icon for Sheridan PubFactory
Loading ...
Support Center